5月5日 - ** 药物开发商Capricor Therapeutics CAPR.O股价下跌14.12%至10.19美元
** CAPR称FDA已确认 (link)，有意召开咨询委员会会议，讨论该公司的实验性细胞疗法
** 称正式日期尚未确定
** 公司正在寻求批准其疗法 deramiocel 用于治疗杜氏肌营养不良症患者(DMD) 心肌病
** DMD心肌病是一种心肌并发症，可发生在遗传性疾病患者身上，导致进行性肌无力。
** 我们认为德米诺赛尔仍有望按要求的标签获得批准，并认为今天的股价疲软是不必要的"--H.C. Wainwright 分析师 Joseph Pantginis
** FDA 将于 8 月 31 日前做出决定
** 截至上次收盘，股价累计下跌约 24
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.